Pfizer Inc.· @pfizer · X·· 2026-08-28AI 评分12
AI 导读
随着 #ESCCongress 2026 重返慕尼黑，早期诊断和及早治疗仍是改善 ATTR-CM 结局的最大机会——ATTR-CM 是一种被低估的心力衰竭病因。 探索该领域如何演变以及接下来需要做什么：https://bit.ly/3UIiVV0
正文
As #ESCCongress 2026 returns to Munich, early diagnosis and treatment initiation remain the biggest opportunity to improve outcomes in ATTR-CM, an underdiagnosed cause of heart failure.
Explore how the landscape has evolved and what needs to happen next: https://bit.ly/3UIiVV0
来源：Pfizer Inc. · x.com